Statements (29)
| Predicate | Object |
|---|---|
| gptkbp:instanceOf |
gptkb:drug
|
| gptkbp:approvedBy |
gptkb:FDA
1997 |
| gptkbp:ATCCode |
D11AX10
|
| gptkbp:brand |
gptkb:finasteride
|
| gptkbp:CASNumber |
98319-26-7
|
| gptkbp:chemicalFormula |
C23H36N2O2
|
| gptkbp:contraindication |
pregnancy
|
| gptkbp:eliminatedIn |
urine
feces |
| gptkbp:form |
gptkb:tablet
|
| gptkbp:halfLife |
4.8-6 hours
|
| https://www.w3.org/2000/01/rdf-schema#label |
Propecia
|
| gptkbp:indication |
androgenetic alopecia
benign prostatic hyperplasia (off-label) |
| gptkbp:legalStatus |
prescription only
|
| gptkbp:manufacturer |
gptkb:Merck_&_Co.
|
| gptkbp:mechanismOfAction |
5-alpha-reductase inhibitor
|
| gptkbp:notRecommendedFor |
gptkb:women
children |
| gptkbp:pregnancyCategory |
gptkb:X_(US)
|
| gptkbp:routeOfAdministration |
oral
|
| gptkbp:sideEffect |
decreased libido
erectile dysfunction ejaculation disorder |
| gptkbp:synonym |
finasteride 1 mg
|
| gptkbp:usedFor |
male pattern baldness
|
| gptkbp:bfsParent |
gptkb:Merck_&_Co.
|
| gptkbp:bfsLayer |
4
|